Hypera S.A. Announces Consolidated Earnings Results for the Second Quarter and First Half Ended June 30, 2021
July 23, 2021 at 08:26 pm EDT
Share
Hypera S.A. announced consolidated earnings results for the second quarter and first half ended June 30, 2020. For the quarter, the company reported net revenue of BRL 1,507,379,000 against BRL 1,050,494,000 a year ago. Income for the period was BRL 470,583,000 against BRL 396,413,000 a year ago. Earnings per share was BRL 0.75 against BRL 0.63 a year ago.
For the first half, the company reported net revenue of BRL 2,678,241,000 against BRL 1,865,526,000 a year ago. Income for the period was BRL 775,675,000 against BRL 634,622,000 a year ago. Earnings per share was BRL 1.23 against BRL 1.01 a year ago.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
